AstraZeneca buys into startup RQ Bio’s COVID antibodies
Brand new UK startup RQ Biotechnology has been thrust into the spotlight after signing a $157 million licensing deal with AstraZeneca for monoclonal antibodies intended to protect vulnerable and immunosuppressed people from COVID-19. The deal covers a portfolio of early-stage antibodies targeting SARS-CoV-2, adding to the pipeline of COVID drugs following AZ’s already available Evusheld […]